Possible modulation of concurrent Parkinson's disease in the management of metastatic GIST: a review of two cases.
J R Coll Physicians Edinb
; 48(3): 242-245, 2018 Sep.
Article
em En
| MEDLINE
| ID: mdl-30191913
ABSTRACT
Imatinib, a tyrosine kinase inhibitor, is the mainstay of treatment for resected high-risk (adjuvant and metastatic) gastrointestinal stromal tumour (GIST) - a rare form of sarcoma. There has been recent research into the neuroprotective role and modulation of dopaminergic neurones by imatinib through the abl pathway in Parkinson's disease (PD). We describe two patients from a single cancer centre with concurrent diagnoses of PD and metastatic GIST receiving imatinib and standard PD management. The cases highlight a potential reduction in PD progression using Unified Parkinson's Disease Rating Scale. Further research into repurposing of imatinib for PD may provide additional management options for this neurodegenerative illness.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Neoplasias Gástricas
/
Tumores do Estroma Gastrointestinal
/
Mesilato de Imatinib
/
Neoplasias Hepáticas
/
Antineoplásicos
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
J R Coll Physicians Edinb
Assunto da revista:
EDUCACAO
/
HISTORIA DA MEDICINA
/
MEDICINA
Ano de publicação:
2018
Tipo de documento:
Article